PETACC-3

Regimen

Experimental
FOLFIRI (infusional LV5FU2 + irinotecan 180 mg/m² Q2W)
Control
Infusional LV5FU2 alone (de Gramont regimen)

Population

Stage II and III colon cancer; primary efficacy analysis in stage III (N=2,094), adjuvant irinotecan-based chemotherapy.

Key finding

NEGATIVE: 5-year DFS irinotecan/LV5FU2 56.7% vs LV5FU2 54.3% (P=.106, not significant); 5-year OS 73.6% vs 71.3% (P=.094). Increased grade 3-4 GI toxicity and neutropenia. Confirms CALGB 89803 finding: irinotecan has no adjuvant colon benefit.

Source: PMID 19451425

Timeline

    Guideline citations

    • NCCN Colon (p.96)